NASDAQ:AMLX Amylyx Pharmaceuticals (AMLX) Stock Forecast, Price & News $26.25 +0.11 (+0.42%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$25.43▼$26.2850-Day Range$24.04▼$31.4252-Week Range$12.39▼$41.93Volume483,423 shsAverage Volume937,676 shsMarket Capitalization$1.76 billionP/E RatioN/ADividend YieldN/APrice Target$50.17 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Amylyx Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside91.1% Upside$50.17 Price TargetShort InterestBearish20.13% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.40Based on 10 Articles This WeekInsider TradingSelling Shares$17.32 M Sold Last QuarterProj. Earnings Growth650.00%From $0.42 to $3.15 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.65 out of 5 starsMedical Sector72nd out of 986 stocksPharmaceutical Preparations Industry28th out of 472 stocks 3.4 Analyst's Opinion Consensus RatingAmylyx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $50.17, Amylyx Pharmaceuticals has a forecasted upside of 91.1% from its current price of $26.25.Amount of Analyst CoverageAmylyx Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted20.13% of the float of Amylyx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmylyx Pharmaceuticals has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Amylyx Pharmaceuticals has recently increased by 24.16%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmylyx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmylyx Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AMLX. Previous Next 3.0 News and Social Media Coverage News SentimentAmylyx Pharmaceuticals has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Amylyx Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest25 people have searched for AMLX on MarketBeat in the last 30 days. This is an increase of 79% compared to the previous 30 days.MarketBeat Follows6 people have added Amylyx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amylyx Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,324,496.00 in company stock.Percentage Held by Insiders12.70% of the stock of Amylyx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.55% of the stock of Amylyx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Amylyx Pharmaceuticals are expected to grow by 650.00% in the coming year, from $0.42 to $3.15 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amylyx Pharmaceuticals is -10.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amylyx Pharmaceuticals is -10.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioAmylyx Pharmaceuticals has a PEG Ratio of 0.94. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioAmylyx Pharmaceuticals has a P/B Ratio of 5.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Amylyx Pharmaceuticals (NASDAQ:AMLX) StockAmylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More Receive AMLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AMLX Stock News HeadlinesMay 16, 2023 | marketbeat.comAmylyx Pharmaceuticals Turns Profitable On Successful Drug LaunchAmylyx Pharmaceuticals is the rare young biotech that's profitable. The company earned $0.02 a share in Q1, and analysts expect profitability to grow.June 6, 2023 | finance.yahoo.comAmylyx Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare ConferenceJune 9, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.June 3, 2023 | americanbankingnews.comSVB Leerink Equities Analysts Boost Earnings Estimates for Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)June 2, 2023 | americanbankingnews.comEquities Analysts Offer Predictions for Amylyx Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:AMLX)June 1, 2023 | reuters.comAmylyx says European panel unlikely to endorse ALS drugMay 31, 2023 | msn.comAmylyx Pharmaceuticals: Post Q1 Selloff Appears OverdoneMay 30, 2023 | reuters.comAmylyx says European drug regulator likely to reject ALS drugJune 9, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 30, 2023 | finance.yahoo.comAmylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European UnionMay 29, 2023 | americanbankingnews.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Sees Large Growth in Short InterestMay 24, 2023 | americanbankingnews.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Rating of "Moderate Buy" from AnalystsMay 22, 2023 | markets.businessinsider.comMizuho Securities Remains a Buy on Amylyx Pharmaceuticals Inc (AMLX)May 20, 2023 | americanbankingnews.comInsider Selling: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Sells $347,343.95 in StockMay 18, 2023 | americanbankingnews.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Trading Down 6% Following Analyst DowngradeMay 17, 2023 | americanbankingnews.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) to Post FY2026 Earnings of $3.35 Per Share, HC Wainwright ForecastsMay 17, 2023 | americanbankingnews.comAmylyx Pharmaceuticals, Inc. to Post Q4 2023 Earnings of $0.62 Per Share, SVB Leerink Forecasts (NASDAQ:AMLX)May 16, 2023 | finance.yahoo.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2023 Earnings Call TranscriptMay 16, 2023 | msn.comMizuho Maintains Amylyx Pharmaceuticals (AMLX) Buy RecommendationMay 16, 2023 | finance.yahoo.comNew Forecasts: Here's What Analysts Think The Future Holds For Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)May 16, 2023 | americanbankingnews.comAnalyzing Amylyx Pharmaceuticals (AMLX) & Its RivalsMay 15, 2023 | americanbankingnews.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Lowered to $50.00 at MizuhoMay 15, 2023 | seekingalpha.comAmylyx: A Biotech Underdog's Resilient Performance And Promising Market PotentialMay 14, 2023 | finance.yahoo.comAmylyx Pharmaceuticals, Inc. Just Reported A Surprise Profit, And Analysts Lifted Their EstimatesMay 12, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Rain Therapeutics (RAIN), Amylyx Pharmaceuticals Inc (AMLX) and Applied DNA Sciences (APDN)May 12, 2023 | msn.comAmylyx Up after Better-than-Expected Q1 ResultsMay 11, 2023 | finance.yahoo.comAmylyx Pharmaceuticals Reports First Quarter 2023 Financial ResultsSee More Headlines AMLX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMLX Company Calendar Last Earnings3/13/2023Today6/08/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AMLX CUSIPN/A CIK1658551 Webamylyx.com Phone617-682-0917FaxN/AEmployees296Year FoundedN/APrice Target and Rating Average Stock Price Forecast$50.17 High Stock Price Forecast$54.00 Low Stock Price Forecast$47.00 Forecasted Upside/Downside+91.1%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.48) Trailing P/E RatioN/A Forward P/E Ratio62.50 P/E Growth0.94Net Income$-198,380,000.00 Net MarginsN/A Pretax Margin-158.55% Return on Equity-57.84% Return on Assets-49.40% Debt Debt-to-Equity RatioN/A Current Ratio7.54 Quick Ratio7.28 Sales & Book Value Annual Sales$22.23 million Price / Sales79.33 Cash FlowN/A Price / Cash FlowN/A Book Value$5.14 per share Price / Book5.11Miscellaneous Outstanding Shares67,180,000Free Float58,645,000Market Cap$1.76 billion OptionableNot Optionable Beta-0.86 Key ExecutivesMr. Joshua B. Cohen (Age 31)Co-Founder, Co-CEO & Director Comp: $1MMr. Justin B. Klee (Age 32)Co-Founder, Co-CEO & Director Comp: $1MMr. James M. Frates M.B.A. (Age 56)Chief Financial Officer Comp: $695.12kMs. Gina M. Mazzariello (Age 52)Chief Legal Officer & Gen. Counsel Comp: $794.83kMr. Tom HolmesChief Technical Operations OfficerMs. Shauna HorvathHead of Global MarketingMs. Debra L. Canner (Age 64)Global Head of HR & CHRO Ms. Margaret M. Olinger M.B.A (Age 58)Global Head of Commercial & Chief Commercial Officer Dr. Patrick D. Yeramian M.D. (Age 64)MBA, Ph.D., Global Head of Clinical R&D and Chief Medical Officer Mr. Chris AielloHead of Canada & GMMore ExecutivesKey CompetitorsIronwood PharmaceuticalsNASDAQ:IRWDChinook TherapeuticsNASDAQ:KDNYProtagonist TherapeuticsNASDAQ:PTGXXencorNASDAQ:XNCRPacira BioSciencesNASDAQ:PCRXView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCBought 7,300 shares on 6/1/2023Ownership: 0.011%ProShare Advisors LLCSold 1,440 shares on 5/26/2023Ownership: 0.016%Ameriprise Financial Inc.Bought 8,377 shares on 5/22/2023Ownership: 0.316%Putnam Investments LLCBought 25,289 shares on 5/22/2023Ownership: 0.072%New York State Common Retirement FundSold 6,972 shares on 5/18/2023Ownership: 0.040%View All Insider TransactionsView All Institutional Transactions AMLX Stock - Frequently Asked Questions Should I buy or sell Amylyx Pharmaceuticals stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amylyx Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AMLX shares. View AMLX analyst ratings or view top-rated stocks. What is Amylyx Pharmaceuticals' stock price forecast for 2023? 6 equities research analysts have issued 12 month target prices for Amylyx Pharmaceuticals' stock. Their AMLX share price forecasts range from $47.00 to $54.00. On average, they expect the company's stock price to reach $50.17 in the next year. This suggests a possible upside of 91.1% from the stock's current price. View analysts price targets for AMLX or view top-rated stocks among Wall Street analysts. How have AMLX shares performed in 2023? Amylyx Pharmaceuticals' stock was trading at $36.95 at the beginning of 2023. Since then, AMLX stock has decreased by 29.0% and is now trading at $26.25. View the best growth stocks for 2023 here. Are investors shorting Amylyx Pharmaceuticals? Amylyx Pharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 8,530,000 shares, an increase of 24.2% from the April 30th total of 6,870,000 shares. Based on an average daily trading volume, of 948,300 shares, the days-to-cover ratio is currently 9.0 days. Approximately 20.1% of the shares of the stock are short sold. View Amylyx Pharmaceuticals' Short Interest. When is Amylyx Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our AMLX earnings forecast. How were Amylyx Pharmaceuticals' earnings last quarter? Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) issued its earnings results on Monday, March, 13th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.12. The business had revenue of $21.89 million for the quarter, compared to analysts' expectations of $3.05 million. What ETFs hold Amylyx Pharmaceuticals' stock? ETFs with the largest weight of Amylyx Pharmaceuticals (NASDAQ:AMLX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Simplify Health Care ETF (PINK), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC) and Invesco DWA SmallCap Momentum ETF (DWAS). When did Amylyx Pharmaceuticals IPO? (AMLX) raised $190 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 10,000,000 shares at a price of $18.00-$20.00 per share. What is Amylyx Pharmaceuticals' stock symbol? Amylyx Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMLX." Who are Amylyx Pharmaceuticals' major shareholders? Amylyx Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (8.99%), BlackRock Inc. (5.39%), Federated Hermes Inc. (2.75%), Pictet Asset Management SA (2.14%), State Street Corp (1.59%) and Emerald Advisers LLC (1.45%). Insiders that own company stock include George M Milne Jr, Gina Mazzariello, Global Investors Lp Viking, James M Frates, Justin B Klee, Morningside Venture Investment and Patrick D Yeramian. View institutional ownership trends. How do I buy shares of Amylyx Pharmaceuticals? Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Amylyx Pharmaceuticals' stock price today? One share of AMLX stock can currently be purchased for approximately $26.25. How much money does Amylyx Pharmaceuticals make? Amylyx Pharmaceuticals (NASDAQ:AMLX) has a market capitalization of $1.76 billion and generates $22.23 million in revenue each year. The company earns $-198,380,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis. How many employees does Amylyx Pharmaceuticals have? The company employs 296 workers across the globe. How can I contact Amylyx Pharmaceuticals? The official website for the company is amylyx.com. The company can be reached via phone at 617-682-0917 or via email at investors@amylyx.com. This page (NASDAQ:AMLX) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.